Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

Capital Reduction

24 Aug 2016 17:16

RNS Number : 0706I
Premier Veterinary Group PLC
24 August 2016
 

PREMIER VETERINARY GROUP PLC

("PVG" or the "Company")

Capital Reduction

 

 

Premier Veterinary Group plc announces that, further to a resolution passed by Shareholders at the Annual General Meeting held on 23 March 2016, in order to facilitate the proposed reduction of PVG's share capital (the "Capital Reduction"), full details of which were set out in the Notice of Annual General Meeting dated 28 January 2016 (the "Notice"), the Company has today issued and allotted 1,690,315 deferred shares of 90 pence each (the "Deferred Shares") to Sue Steven, the Secretary of the Company.

The deferred shares do not entitle holders to receive notice of or attend and vote at any general meeting of the Company or to receive a dividend or other distribution or to participate in any return on capital on a winding up other than the nominal amount paid on such shares following a substantial distribution to the holders of ordinary shares in the Company. Accordingly, the deferred shares are, for all practical purposes, valueless.

As set out in the Notice, the share capital of the Company will be reduced by cancelling and extinguishing both the Deferred Shares together with all other deferred shares of 90 pence each in the capital of the Company on 30 August 2016.

The Company is in the process of making an application to the High Court of Justice, Chancery Division, for approval for the reduction of PVG's share capital and cancellation of the entire amount standing to the credit of the Company's share premium account.

A further announcement will be issued in due course.

 

For further information, please contact:

Premier Veterinary Group plc Tel: +44 (0)117 970 4130

Dominic Tonner, Chief Executive Officer

Daniel Smith, Chief Financial Officer

 

Zeus Capital Limited Tel: +44 (0)203 829 5000

Giles Balleny, Director, Corporate Finance

Hugh Kingsmill Moore, Director, Sales 

 

Square1 Consulting Tel: +44 (0)207 929 5599

David Bick/Brian Alexander

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CARQZLFLQVFFBBF
Date   Source Headline
21st Feb 20117:00 amRNSBoard Change
11th Feb 20117:00 amRNSNotice of Results
8th Feb 20117:00 amRNSDisposal of Majority of Woundcare Business
20th Jan 201112:25 pmRNSHolding(s) in Company
4th Jan 20111:19 pmRNSTotal Voting Rights
16th Dec 20107:00 amRNSChange of Adviser
6th Dec 20109:40 amRNSBlocklisting Interim Review
29th Nov 20101:06 pmRNSHolding(s) in Company
29th Nov 20107:00 amRNSPositive results for pre-clinical product EG013
11th Nov 20107:00 amRNSInterim Management Statement
8th Nov 20102:21 pmRNSHolding(s) in Company
23rd Sep 20104:40 pmRNSSecond Price Monitoring Extn
23rd Sep 20104:35 pmRNSPrice Monitoring Extension
14th Sep 20104:21 pmRNSHolding(s) in Company
14th Sep 20104:19 pmRNSHolding(s) in Company
13th Sep 20103:29 pmRNSDirector/PDMR Shareholding
9th Sep 20107:00 amRNSStrategic Review
31st Aug 201010:33 amRNSTotal Voting Rights
27th Aug 201010:08 amRNSForm 8.5 (EPT/NON-RI)
25th Aug 20107:00 amRNSHalf Yearly Report
20th Aug 20102:27 pmPRNForm 8.3 - Ark Therapeutics Group Plc
19th Aug 201011:35 amRNSForm 8.5 (EPT/NON-RI)
16th Aug 201012:29 pmRNSForm 8.3 - Ark Therapeutics Group plc
16th Aug 20107:00 amRNSForm 8.3 - Ark Therapeutics PLC (Amendment)
13th Aug 20104:24 pmRNSRe EGM
13th Aug 201011:34 amRNSForm 8.5 (EPT/NON-RI)
13th Aug 201011:22 amRNSForm 8.5 (EPT/RI)
13th Aug 201010:30 amRNSForm 8.3 - Ark Therapeutics PLC
11th Aug 201011:35 amRNSForm 8.3 - [Ark Therapeutics Plc]
5th Aug 201012:31 pmRNSForm 8.3 - Ark Therapeutics Group PLC
4th Aug 20104:41 pmRNSSecond Price Monitoring Extn
4th Aug 20104:35 pmRNSPrice Monitoring Extension
4th Aug 201010:00 amRNSForm 8.3 - Ark Therapeutics Group
3rd Aug 201010:47 amRNSForm 8.3 - Ark Therapeutics
30th Jul 201011:22 amRNSForm 8.3 - Ark Therapeutics Plc
29th Jul 201010:34 amRNSForm 8.5 (EPT/NON-RI)
28th Jul 201011:03 amRNSForm 8.5 (EPT/NON-RI)
28th Jul 201010:36 amRNSHolding(s) in Company
28th Jul 201010:30 amRNSForm 8.3 - Ark Therapeutics
28th Jul 201010:01 amRNSHolding(s) in Company
26th Jul 20102:57 pmRNSForm 8.3 - [Ark Therapeutics]
26th Jul 20102:41 pmPRNForm 8.3 - ARK THERAPEUTICS
26th Jul 201011:37 amRNSForm 8.5 (EPT/NON-RI)
23rd Jul 201011:57 amRNSForm 8.5 (EPT/NON-RI)
23rd Jul 201011:15 amRNSForm 8.3 - Ark Therapeutics Group plc
22nd Jul 20102:34 pmPRNForm 8.3 - Ark Theraputics Plc
22nd Jul 201012:54 pmRNSForm 8.3 - Ark Therapeutics Group plc
22nd Jul 201011:19 amRNSForm 8.5 (EPT/NON-RI)
22nd Jul 201010:55 amRNSForm 8.3 - Ark Therapeutics Group Plc
21st Jul 20102:41 pmRNSForm 8.3 - Ark Therapeutics Plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.